NurExone Secures Australian Patent for Stem Cell-Derived Exosome Production
Event summary
- NurExone Biologic Inc. received an Australian patent (No. 2020303456) for stem cell-derived exosome production, valid until June 10, 2040.
- The patent is licensed exclusively from Technion Research and Development Foundation Limited.
- NurExone's CEO, Dr. Lior Shaltiel, emphasized the patent's role in enabling scalable, reproducible exosome production for therapeutic development.
- The company is expanding its international patent portfolio, with prior grants in Israel and the U.S., and additional applications under examination.
- NurExone's ExoPTEN will be featured in a scientific presentation on optic nerve regeneration at ISCEV@Denver on May 2, 2026.
The big picture
NurExone's Australian patent grant strengthens its position in the regenerative medicine space, particularly for central nervous system injuries. The company's focus on scalable exosome production aligns with broader industry trends toward advanced biomanufacturing and personalized therapies. The strategic expansion of its IP portfolio underscores NurExone's efforts to dominate key markets ahead of potential clinical trials and commercialization.
What we're watching
- IP Expansion
- Whether NurExone can sustain its international patent portfolio growth to secure key commercial and regulatory markets.
- Manufacturing Scale
- The pace at which NurExone builds manufacturing capacity, particularly with its LOI with BioXtek.
- Clinical Translation
- How preclinical data for ExoPTEN in optic nerve regeneration will translate into clinical trial success.
Related topics